EpicentRx
  • Vision
    • Culture
    • Team
  • Pipeline
    • Pipeline Overview
    • Clinical Trials
  • Technologies
    • AdAPT™ Platform
    • CyNRGY™ (RRx-001)
  • News
    • Press Releases
    • Media
    • Conferences
    • Blog
  • Blog
  • Careers
  • Contact Us
Select Page
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205.PMID: 27007055 Free PMC article. Review.
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27.PMID: 27118403 Free PMC article.
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016.PMID: 27840583 Free...
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.Oncol Res Treat. 2016;39(11):720-723. doi: 10.1159/000449432. Epub 2016 Sep 19.PMID: 27855386
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. PMID: 28444622.
« Older Entries
Next Entries »
858.947.6635
11099 North Torrey Pines Road
Suite 160
La Jolla, CA 92037
Follow Us
  • Follow
  • Follow
Subscribe to our newsletter

This field is for validation purposes and should be left unchanged.

© 2023 EpicentRx, Inc. All rights reserved.